Showing results (1121-1130 of 1,219) with videos related to

Sort By:
Pageof 122
CA: a Cancer Journal for Clinicians|January 20, 2016
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineMichael W Kattan, Kenneth R Hess, Mahul B Amin, et al.
Annals of Surgical Oncology|March 22, 2001
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival durationT M Breslin, K R Hess, D B Harbison, et al.
Neuro-Oncology|December 6, 2013
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionJason Beiko, Dima Suki, Kenneth R Hess, et al.
Cancer|March 27, 2018
Development of CNS metastases and survival in patients with inflammatory breast cancerMarc I Uemura, John T French, Kenneth R Hess, et al.
Chembiochem : a European Journal of Chemical Biology|November 10, 2019
Rapid Biophysical Characterization and NMR Spectroscopy Structural Analysis of Small Proteins from Bacteria and ArchaeaNina Kubatova, Dennis J Pyper, Hendrik R A Jonker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Neuro-Oncology|March 5, 2008
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesMorris D Groves, Michael J Glantz, Marc C Chamberlain, et al.
JCO Precision Oncology|October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyApostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
The Lancet. Oncology|March 3, 2007
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling studyYun Gong, Kai Yan, Feng Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatinRoy S Herbst, Nizar A Mullani, Darren W Davis, et al.
Pageof 122